Commodore Capital’s Kronos Bio KRON Stock Holding History

Commodore Capital’s Portfolio KRON Stock Details KRON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-298,839	Closed	-$4.06M	–	29
2021 Q4	$4.06M	Hold	298,839	–	–	0.94%	19
2021 Q3	$6.26M	Hold	298,839	–	–	1.65%	19
2021 Q2	$7.16M	Hold	298,839	–	–	2.49%	16
2021 Q1	$8.75M	Hold	298,839	–	–	3.48%	10
2020 Q4	$8.93M	Buy	+298,839	New	+$9.38M	4.85%	5

Other funds holding KRON

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Commodore Capital's KRON Position: Q1 2022 in Review

Commodore Capital sold out of Kronos Bio (KRON) in Q1 2022, closing a stake of 298,839 shares — an estimated $4.06M sold.

Commodore Capital first reported a position in KRON in Q4 2020 and held it in 5 quarters. The position peaked at $8.93M in Q4 2020. 96 funds tracked by Wall St. Rank hold KRON as of Q1 2022.

Commodore Capital reported no remaining Kronos Bio position as of Q1 2022 after selling out during the quarter.
Commodore Capital sold 298,839 Kronos Bio shares in Q1 2022, an estimated $4.06M.
Commodore Capital first reported a position in Kronos Bio in Q4 2020 and held it in 5 quarters.
Commodore Capital's Kronos Bio position peaked at $8.93M in Q4 2020.
96 funds tracked by Wall St. Rank held Kronos Bio as of Q1 2022.

Based on Commodore Capital's 13F filing for Q1 2022, filed 16 May 2022.